Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas

Lee, Ho Yun; Jae, Min; Lee, Kyung Soo; Lee, Hee Young; Kwon, O Jung; Choi, Joon Young; Kim, Hong Kwan; Choi, Yong Soo; Kim, Young Tae; Shim, Young Mog

doi:10.1016/j.jtho.2016.03.011

Cited by 84 publications

(97 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When compared with 5 major nonmucinous adenocarcinoma subtypes, the DFS and OS curves of IMA were running between ACN/PAP and SOL/MIP subgroups. These results were consistent with our (Cai et al 2014) and other's (Lee et al 2016) previous similar studies. To distinguish the impact of mixed nonmucinous component on patients' prognosis, further analyses demonstrated the DFS and OS curves of pure mucinous were closely to lepidic adenocarcinoma, with a nearly 100 % 5-year disease free survival.…”

Section: Discussionsupporting

confidence: 94%

“…Clinically, IMA have a tendency for multicentric, multilobar involvement (Travis et al 2011). The prognosis of IMA remains controversial (Cai et al 2014;Eberhard et al 2005;Lee et al 2016;Warth et al 2012;Yanagawa et al 2013). Previous reports demonstrated that IMA have a correlation with poor prognosis (Yanagawa et al 2013).…”

Section: Introductionmentioning

confidence: 99%

“…The new classification is a useful predictive tool for invasive nonmucinous adenocarcinoma for its reproducibility. In contrast to nonmucinous adenocarcinoma, limited information has been reported for the prognosis of IMA with different percentage of invasive mucinous pattern (Cai et al 2014;Lee et al 2016). Also, there were still little known about the effect of traditional first line platinumbased adjuvant chemotherapy on early stage IMA patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

Luo

Wang

Han

et al. 2016

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

Luo

Wang

Han

et al. 2016

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…However, this negative value in terms of prognosis was not an independent factor by multivariate analysis. It is known that TTF1 expression is a favorable prognostic factor, and prognosis of the invasive mucinous tumors is inferior to that of low‐grade non‐mucinous tumors in lung adenocarcinoma . As VSIG1 expression in lung adenocarcinomas was confounded with a loss of TTF1 expression, invasive mucinous subtype, and advanced disease stage, the results of survival analyses should be interpreted cautiously.…”

Section: Discussionmentioning

confidence: 99%

Characterization of V‐set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells

et al. 2017

View full text Add to dashboard Cite

V‐set and immunoglobulin domain containing 1 (VSIG1) is a newly discovered member of the immunoglobulin superfamily of proteins, expressed in normal stomach and testis. In cancers, however, the clinical and biological roles of VSIG1 remain unknown. Here we investigated VSIG1 expression in 11 cancers and assessed the prognostic roles of VSIG1 in patients with gastric cancer (GC) (n = 362) and non‐small‐cell lung cancer (n = 650). V‐set and immunoglobulin domain containing 1 was downregulated in 60.5% of GC specimens, and high VSIG1 expression was identified as an independent favorable prognostic factor for overall survival in GC patients (hazard ratio, 0.58; 95% confidence interval, 0.35–0.96). Among lung adenocarcinomas (n = 428), VSIG1 was significantly and inversely associated with thyroid transcription factor 1 expression and was frequently expressed in the invasive mucinous subtype (17 of 19, 89.5%). In addition, VSIG1 was expressed in a subset of pancreatic, ovarian, and prostate cancers. The variant 2 VSIG1 transcript was the dominant form in these tissues and cancer cells. Introduction of VSIG1 significantly reduced the proliferative ability of MKN1 and MKN28 GC cells and H1299 lung cancer cells and downregulated cell migration of these cells, as well as of KYSE150, an esophageal cancer cell line. Cell invasion of MKN1, MKN28, and KYSE150 cells was also reduced by VSIG1 introduction. In vitro characterization revealed that VSIG1 forms homodimers through homophilic cis‐interactions but not through homophilic trans‐interactions. These results suggest that VSIG1 possesses tumor suppressive functions that are translated into favorable prognosis of VSIG1‐expressing GC patients.

show abstract

“…1,2 IMA is defined as adenocarcinoma that is characterized by a goblet or columnar cell morphology with abundant intracytoplasmic mucin. 2 Although the clinical, pathological, and genetic characteristics of IMA have been revealed in recent reports, [3][4][5][6][7][8][9][10][11][12][13] the prognosis and prognostic factors have not yet been clarified, due to its rare incidence as it accounts for only 5% of all lung adenocarcinomas. 2 In previous studies, IMA had distinct clinical, pathological, and genetic differences from non-mucinous adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

Proportion of goblet cell is associated with malignant potential in invasive mucinous adenocarcinoma of the lung

Oki

Aokage

Ueda

et al. 2019

Pathology International

View full text Add to dashboard Cite

Invasive mucinous adenocarcinoma (IMA) is a newly classified variant of lung adenocarcinoma. The aim of this study was to examine the correlation between the proportion of goblet cells and the clinicopathological characteristics of IMA. Ninety‐nine patients with stage I IMA were included in this study. We estimated prognostic impact of goblet cell proportion. We classified them into two groups: the cases with a high goblet cell proportion (HGP, goblet cell proportion ≥80%) and the cases with a low goblet cell proportion (LGP, goblet cell proportion ≤30%), and compared the expression levels of five cancer progression markers and the number of tumor‐promoting stromal cells between the two groups. Univariate and multivariate analysis revealed that the goblet cell proportion was a prognostic factor for recurrence free survival (P < 0.01) and overall survival (P = 0.01). The expression levels of the cancer stem cell‐related marker, ALDH‐1, and proliferation‐related marker, geminin were significantly higher in the LGP group than in the HGP group. CD204+ tumor‐associated macrophages were significantly more in the LGP stroma than the HGP stroma. Our current study indicated that the proportion of goblet cells was correlated with the malignant potential in surgically resected IMA.

show abstract

Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas

Cited by 84 publications

References 29 publications

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

Characterization of V‐set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells

Proportion of goblet cell is associated with malignant potential in invasive mucinous adenocarcinoma of the lung

Contact Info

Product

Resources

About